Zobrazeno 1 - 10
of 16
pro vyhledávání: '"MJ Morales-Lara"'
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Rituximab is a chimeric, anti-CD20 monoclonal antibody. In addition to its approved indications, its off-label use has increased in the management of a variety of neurological diseases. Aim and objectives To describe rituxim
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Immunosuppression related to organ transplant is a risk factor for multidrug resistant infections. Aim and objectives To evaluate the prevalence of nosocomial infections (NI) by multidrug resistant (MDR) pathogens, aetiologi
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Fingolimod is an approved drug for relapsing–remitting multiple sclerosis (RRMS). Oral treatments allow better quality of life than injectable drugs but are not harmless. Aim and objectives To assess fingolimod safety in p
Publikováno v:
Eur J Hosp Pharm
Background It is considered that 30% to 50% of antibiotic prescriptions in the Emergency Department (ED) are inappropriate. Urinary tract infections (UTI) are one of the most commonly diagnosed infections in the ED. Purpose To assess the appropriaten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3727810281ecf13991f48680e32afd01
https://europepmc.org/articles/PMC7535381/
https://europepmc.org/articles/PMC7535381/
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that selectively targets CD52, resulting in depletion and subsequent distinct repopulation of circulating T and B lymphocytes. PURPOSE: To evaluate the effectiveness and security of alemtuzum
Publikováno v:
Eur J Hosp Pharm
Background Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopaenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (T
Publikováno v:
Clinical pharmacy.
Background Natalizumab is a selective adhesion molecule inhibitor and binds to the α4 subunit of human integrins. Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks (standard dose). Purpose To evaluate and compare the effe
Publikováno v:
Drug information and pharmacotherapy.
Background Fosfomycin trometamol is a broad spectrum antibiotic used in uncomplicated, low urinary tract infections (UTI) in women. Purpose To describe the use of fosfomycin trometamol in UTI in a third level hospital. Material and methods Hospitalis
Autor:
MJ Morales Lara, I Muñoz Castillo, L Yunquera Romero, C Ortega de la Cruz, P Conesa Zamora, C González Pérez-Crespo
Publikováno v:
Patient safety and risk management.
Background Drug related problems (DRP) are defined as negative clinical outcomes resulting from pharmacotherapy, which do not achieve therapy objectives or produce undesirable effects. They can be necessity, safety or effectiveness DRP. Purpose To me
Publikováno v:
European Journal of Hospital Pharmacy. 23:A238.2-A239
Background Polypharmacy is a risk factor for geriatric syndrome, increasing morbidity and mortality. Purpose To determine the prevalence of potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs) in older people with